Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study.

ABSTRACT:

Introduction

Prophylactic administration of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NAs) is the standard treatment for controlling hepatitis B virus (HBV) recurrence after liver transplantation (LT). Since lifelong use of HBIG is expensive and inconvenient and the antibodies level in anti-hepatitis B surface (HBs) is not sustainable and stable, an alternative strategy is to produce anti-HBs antibodies by active immunization. Our present study aimed to prospectively investigate the efficacy and safety of procedural HBV vaccination in transplanted patients.

Methods

Recipients who had undergone LT for hepatitis B related liver diseases more than one year before, with no evidence of HBV recurrence or rejection and normal liver function were enrolled. All s

SUBMITTER: Yang A 

PROVIDER: S-EPMC5690662 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature